The genomic landscape of tuberous sclerosis complex

Tuberous sclerosis complex (TSC) is a rare genetic disease causing multisystem growth of benign tumours and other hamartomatous lesions, which leads to diverse and debilitating clinical symptoms. Patients are born with TSC1 or TSC2 mutations, and somatic inactivation of wild-type alleles drives MTOR activation; however, second hits to TSC1/TSC2 are not always observed. Here, we present the genomic landscape of TSC hamartomas. We determine that TSC lesions contain a low somatic mutational burden relative to carcinomas, a subset feature large-scale chromosomal aberrations, and highly conserved molecular signatures for each type exist. Analysis of the molecular signatures coupled with computational approaches reveals unique aspects of cellular heterogeneity and cell origin. Using immune data sets, we identify significant neuroinflammation in TSC-associated brain tumours. Taken together, this molecular catalogue of TSC serves as a resource into the origin of these hamartomas and provides a framework that unifies genomic and transcriptomic dimensions for complex tumours.

[1]  Mauricio O. Carneiro,et al.  From FastQ Data to High‐Confidence Variant Calls: The Genome Analysis Toolkit Best Practices Pipeline , 2013, Current protocols in bioinformatics.

[2]  Fred A. Wright,et al.  Integrated study of copy number states and genotype calls using high-density SNP arrays , 2009, Nucleic acids research.

[3]  S. Verhoef,et al.  High rate of mosaicism in tuberous sclerosis complex. , 1999, American journal of human genetics.

[4]  J. Wheless,et al.  Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States , 2007, Genetics in Medicine.

[5]  H. Northrup,et al.  Tuberous Sclerosis Complex Consensus Conference: Revised Clinical Diagnostic Criteria , 1998, Journal of child neurology.

[6]  H. Onda,et al.  Heterozygosity for the tuberous sclerosis complex (TSC) gene products results in increased astrocyte numbers and decreased p27-Kip1 expression in TSC2+/− cells , 2002, Oncogene.

[7]  A. Wilm,et al.  LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets , 2012, Nucleic acids research.

[8]  D. Kwiatkowski,et al.  Sun exposure causes somatic second-hit mutations and angiofibroma development in tuberous sclerosis complex. , 2014, Human molecular genetics.

[9]  A. Stemmer-Rachamimov,et al.  Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions. , 2001, American journal of human genetics.

[10]  Gary D Bader,et al.  Comprehensive identification of mutational cancer driver genes across 12 tumor types , 2013, Scientific Reports.

[11]  A. McMahon,et al.  Atlas of gene expression in the developing kidney at microanatomic resolution. , 2008, Developmental cell.

[12]  A. Byars,et al.  Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. , 2010, The New England journal of medicine.

[13]  H. Kazazian Processed pseudogene insertions in somatic cells , 2014, Mobile DNA.

[14]  G. Zamboni,et al.  The Perivascular Epithelioid Cell and Related Lesions , 1997 .

[15]  D. Kwiatkowski,et al.  Mosaicism in tuberous sclerosis as a potential cause of the failure of molecular diagnosis. , 1999, The New England journal of medicine.

[16]  C. Perou,et al.  Allele-specific copy number analysis of tumors , 2010, Proceedings of the National Academy of Sciences.

[17]  A. Wilfong,et al.  Long-term treatment of epilepsy with everolimus in tuberous sclerosis , 2016, Neurology.

[18]  R. Pieters,et al.  Low frequency of DNMT3A mutations in pediatric AML, and the identification of the OCI-AML3 cell line as an in vitro model , 2012, Leukemia.

[19]  T. Sepp,et al.  Loss of heterozygosity in tuberous sclerosis hamartomas. , 1996, Journal of medical genetics.

[20]  N. Rensing,et al.  Inflammatory mechanisms contribute to the neurological manifestations of tuberous sclerosis complex , 2015, Neurobiology of Disease.

[21]  W. Shi,et al.  The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote , 2013, Nucleic acids research.

[22]  A. Green,et al.  The tuberous sclerosis gene on chromosome 9q34 acts as a growth suppressor. , 1994, Human molecular genetics.

[23]  Hongbing Zhang,et al.  Pathogenesis of Tuberous Sclerosis Subependymal Giant Cell Astrocytomas: Biallelic Inactivation of TSC1 or TSC2 Leads to mTOR Activation , 2004, Journal of neuropathology and experimental neurology.

[24]  Ravi Bhargava,et al.  Cortical tubers, cognition, and epilepsy in tuberous sclerosis. , 2011, Pediatric neurology.

[25]  R. Lazarus,et al.  Identification of 54 large deletions/duplications in TSC1 and TSC2 using MLPA, and genotype-phenotype correlations , 2007, Human Genetics.

[26]  Steven J. M. Jones,et al.  Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. , 2016, The New England journal of medicine.

[27]  T. Robbins,et al.  Renal Involvement in Tuberous Sclerosis , 1991, Annals of the New York Academy of Sciences.

[28]  Andrew Menzies,et al.  Processed pseudogenes acquired somatically during cancer development , 2014, Nature Communications.

[29]  Y. Ben-Ari,et al.  Selective suppression of excessive GluN2C expression rescues early epilepsy in a tuberous sclerosis murine model , 2014, Nature Communications.

[30]  P. Laird,et al.  Low-level processing of Illumina Infinium DNA Methylation BeadArrays , 2013, Nucleic acids research.

[31]  Vincent J Schmithorst,et al.  Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. , 2008, The New England journal of medicine.

[32]  J. Brugarolas,et al.  Simultaneous isolation of high-quality DNA, RNA, miRNA and proteins from tissues for genomic applications , 2013, Nature Protocols.

[33]  D. Kwiatkowski,et al.  Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. , 2001, American journal of human genetics.

[34]  G. Getz,et al.  GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.

[35]  P. V. van Rijen,et al.  Gene Expression Analysis of Tuberous Sclerosis Complex Cortical Tubers Reveals Increased Expression of Adhesion and Inflammatory Factors , 2009, Brain pathology.

[36]  A. Engel,et al.  Cortical Tuber Count: A Biomarker Indicating Neurologic Severity of Tuberous Sclerosis Complex , 1997, Journal of child neurology.

[37]  Kai Ye,et al.  Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads , 2009, Bioinform..

[38]  M. Baybis,et al.  Expression of ICAM-1, TNF-α, NFκB, and MAP kinase in tubers of the tuberous sclerosis complex , 2003, Neurobiology of Disease.

[39]  O. Hofmann,et al.  VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research , 2016, Nucleic acids research.

[40]  B. Scheithauer,et al.  Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. , 1996, American journal of human genetics.

[41]  A. Fernandez-Flores Evidence on the neural crest origin of PEComas. , 2011, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.

[42]  S. Thomas,et al.  Identification and characterization of the tuberous sclerosis gene on chromosome 16 , 1993, Cell.

[43]  Charity W. Law,et al.  voom: precision weights unlock linear model analysis tools for RNA-seq read counts , 2014, Genome Biology.

[44]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[45]  Doron Lancet,et al.  GeneAnalytics: An Integrative Gene Set Analysis Tool for Next Generation Sequencing, RNAseq and Microarray Data , 2016, Omics : a journal of integrative biology.

[46]  E. Aronica,et al.  Inflammatory processes in cortical tubers and subependymal giant cell tumors of tuberous sclerosis complex , 2008, Epilepsy Research.

[47]  J. Osborne,et al.  Epidemiology of Tuberous Sclerosis , 1991, Annals of the New York Academy of Sciences.

[48]  O. Devinsky,et al.  Severity of manifestations in tuberous sclerosis complex in relation to genotype , 2014, Epilepsia.

[49]  Aaron R. Quinlan,et al.  GEMINI: Integrative Exploration of Genetic Variation and Genome Annotations , 2013, PLoS Comput. Biol..

[50]  E. Thiele,et al.  Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial , 2013, The Lancet.

[51]  A. Ouweland,et al.  Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype – phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex , 2005, European Journal of Human Genetics.

[52]  D. Krueger,et al.  Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference , 2013, Pediatric neurology.

[53]  C. Crowson,et al.  Causes of death in patients with tuberous sclerosis. , 1991, Mayo Clinic proceedings.

[54]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[55]  P. Crino,et al.  The tuberous sclerosis complex. , 2006, The New England journal of medicine.

[56]  P. Argani,et al.  Cathepsin K expression in the spectrum of perivascular epithelioid cell (PEC) lesions of the kidney , 2012, Modern Pathology.

[57]  S Povey,et al.  Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. , 1997, Science.

[58]  E. Aronica,et al.  Fetal Brain Lesions in Tuberous Sclerosis Complex: TORC1 Activation and Inflammation , 2013, Brain pathology.

[59]  Alcino J. Silva,et al.  Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis , 2008, Nature Medicine.

[60]  Wei Shi,et al.  featureCounts: an efficient general purpose program for assigning sequence reads to genomic features , 2013, Bioinform..

[61]  J. Krischer,et al.  Efficacy and safety of sirolimus in lymphangioleiomyomatosis. , 2011, The New England journal of medicine.

[62]  Ling Lin,et al.  Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing , 2015, PLoS genetics.

[63]  David Chen,et al.  Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial , 2013, The Lancet.

[64]  W. Stanford,et al.  The neural crest lineage as a driver of disease heterogeneity in Tuberous Sclerosis Complex and Lymphangioleiomyomatosis , 2014, Front. Cell Dev. Biol..

[65]  G. Dressler,et al.  The genetics and epigenetics of kidney development. , 2013, Seminars in nephrology.

[66]  B. Scheithauer,et al.  Markers of cellular proliferation are expressed in cortical tubers , 2003, Annals of neurology.

[67]  F. Cunningham,et al.  The Ensembl Variant Effect Predictor , 2016, Genome Biology.

[68]  J. Xu,et al.  Tsc1 mutant neural stem/progenitor cells exhibit migration deficits and give rise to subependymal lesions in the lateral ventricle. , 2011, Genes & development.

[69]  G. Watkins,et al.  Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes. , 2005, European journal of cancer.

[70]  J. Cheadle,et al.  Cognitive deficits in Tsc1+/−mice in the absence of cerebral lesions and seizures , 2007, Annals of neurology.

[71]  J. Blenis,et al.  Molecular mechanisms of mTOR-mediated translational control , 2009, Nature Reviews Molecular Cell Biology.

[72]  Ash A. Alizadeh,et al.  Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.

[73]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[74]  Zechen Chong,et al.  TransVar: a multilevel variant annotator for precision genomics , 2015, Nature Methods.

[75]  J. García-Verdugo,et al.  Sustained activation of mTOR pathway in embryonic neural stem cells leads to development of tuberous sclerosis complex-associated lesions. , 2011, Cell stem cell.

[76]  A. Knudson Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[77]  P. Finan,et al.  TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1. , 2012, Molecular cell.

[78]  Li Ding,et al.  Retrotransposition of gene transcripts leads to structural variation in mammalian genomes , 2013, Genome Biology.

[79]  Hesheng Liu,et al.  Decreased language laterality in tuberous sclerosis complex: A relationship between language dominance and tuber location as well as history of epilepsy , 2012, Epilepsy & Behavior.

[80]  M. Wigler,et al.  Circular binary segmentation for the analysis of array-based DNA copy number data. , 2004, Biostatistics.

[81]  S. Bosari,et al.  Growth Factors , Cytokines , Cell Cycle Molecules The Methylation of the TSC 2 Promoter Underlies the Abnormal Growth of TSC 2 Angiomyolipoma-Derived Smooth Muscle Cells , 2009 .

[82]  M. DePristo,et al.  A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.

[83]  Ben-Ari FuchsShani,et al.  GeneAnalytics: An Integrative Gene Set Analysis Tool for Next Generation Sequencing, RNAseq and Microarray Data , 2016 .

[84]  Trevor J Pugh,et al.  Whole Exome Sequencing Identifies TSC1/TSC2 Biallelic Loss as the Primary and Sufficient Driver Event for Renal Angiomyolipoma Development , 2016, PLoS genetics.